Apellis (APLS) said Wednesday the New England Journal of Medicine published positive Phase 3 results for Empaveli, its treatment for rare kidney diseases.

The study showed a 68% reduction in proteinuria, the presence of an abnormal amount of protein in the urine, at Week 26, along with stabilization of kidney function and reduced C3 staining, the company said.

Results were consistent across adults and adolescents, including patients whose disease returned after a transplant. Empaveli is already Food and Drug Administration-approved for patients 12 and older.

Shares of the company were up over 1% in after-hours trading.